CKD Bio confirms non-inferiority of CKDB-501A compared to Botox
CKD Bio said it has confirmed the non-inferiority of CKDB-501A, aimed at improving moderate to severe frown lines, compared to Botox through a phase 3 clinical trial's topline results. CKD Bio announced positive